Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy

Susan L. Hobernicht, Bahareh Schweiger, Philip Zeitler, Michael Wang, Stephen P. Hunger

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is caused by the BCR-ABL1 fusion gene that encodes for a constitutively-active tyrosine kinase. Adults and children with CML are typically treated with imatinib mesylate, a BCR-ABL1 tyrosine kinase inhibitor (TKI), or a second-generation TKI. Several case reports have documented growth delay of unknown mechanism in children with CML treated with imatinib. We report a seven-year-old identical twin with CML who developed significant growth delay, as compared to her twin, during five years of TKI therapy. Detailed endocrine evaluation showed acquired growth hormone deficiency, a pathway potentially inhibited by TKIs.

Original languageEnglish
Pages (from-to)671-673
Number of pages3
JournalPediatric Blood and Cancer
Volume56
Issue number4
DOIs
StatePublished - Apr 2011
Externally publishedYes

Keywords

  • CML
  • Dasatinib
  • Growth hormone deficiency
  • Imatinib

Fingerprint

Dive into the research topics of 'Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy'. Together they form a unique fingerprint.

Cite this